ChemComm
Communication
Fig. 3 TEM image of (a) methanolic solution of 0.014 mM methotrexate
solution and (b) methotrexate loaded PMM vesicles after incubation for 2 days;
fluorescence microscopic images showing (c) green fluorescence of the
methotrexate loaded PMM vesicles after incubation for 2 days and (d) rupture
of methotrexate loaded PMM vesicles after 24 h incubation with 10 mM KCl
salt solution; (e) fluorescence emission spectra showing encapsulation and
release of the methotrexate drug at an excitation wavelength of 350 nm.
Fig. 2 Single crystal XRD results of (a) supramolecular b-sheet-like struc-
ture of PMM in the ab plane; (b) higher order self-assembly of the b-sheet
layers in the b-direction. Each sheet-like layer is indicated by a double
headed arrow, and (c) proposed schematic model of formation of various
nano-structures.
solution with 10 mM KCl solution (1 : 1 v/v mixing) for 24 h,
the fluorescence of MTX again increases, confirming effective
drug-release. In Fig. S15 (ESI†), we tried to provide a probable
mechanism of MTX drug penetration through the nano-pores
on the surface of the hollow PMM vesicles. Interestingly, the
vesicles can entrap the drug in its cavity for several days, even
up to 2 months (Fig. S16, ESI†), which indicates the stability of
self-assembly of the nano-vesicles. Notably, the morphological
pattern of the day or month aged MTX drug directly reflects the
morphology of the drug inside the peptide-vesicle (Fig. S16,
ESI†), depicting that there is no chemical interaction of the
PMM with the drug due to protection of the peptide molecule at
both ends and thereby highly recommending it to be utilized as
a drug carrier in therapeutics.
In summary, we have demonstrated the self-assembly of a
new di-peptide mimetic molecule, constituting only un-natural
amino acids, into various nanostructures under various stimu-
lations and its possible application in drug delivery. This newly
described small peptide mimetic molecule not only is attractive
for the model study of peptide interaction behaviours in bio-
logical systems, but also offers novel scaffolds for the future
design of new functional biomaterials.
type of crystal packing is responsible for the formation of
vesicle, tube and fibril/ribbon-like structures.8,19 The formation
of nano-vesicles may be envisaged by considering the wrapping
of the b-sheet-like layers in two different directions simulta-
neously20 as depicted in the schematic model in Fig. 2(c). We
assume that due to thermal treatment or interaction with –CH3
functional groups on different SAM surfaces or the presence of
different solvents, the two-way wrapping of b-sheet layers opens
up and they are arranged side by side to form the fibrils/ribbons
(Fig. 2(c)). Again in a chloroform–methanol solvent mixture (1 : 1 v/v)
and aromatic solvent like toluene, b-sheet-like layers may fold
in only one direction to form the nano-tubes (Fig. 2(c)).8,20
A simple co-relation with the crystal structure and the TEM
images of PMM nanostructures has been provided in Fig. S14 of
ESI,† which also supports our assumption.21
Thus, the self-assembly of m-amino benzoic acid and
a-amino isobutyric acid mediated peptide molecules, without
any electrostatic interactions, supports the fact that various
non-covalent interactions can facilitate the formation of such
well-ordered nano-morphologies.
We thank Dr S. G. Shyu (Academia Sinica) for the support
of XRD.
The design and construction of nano-vesicles from the self-
assembling peptide and pseudo peptides are being considered
as excellent vehicles for encapsulating and carrying drugs,22,23
but the entrapment capability of stable nano-vesicles generated
from small peptide-mimetic molecules is yet to be explored.
Thus, we investigated the efficiency of the PMM based nano-
vesicles to encapsulate the anti-cancer drug Methotrexate
(MTX).24 TEM images of the drug and drug after encapsulation
by the nano-vesicles clearly depict the encapsulation of the
MTX drug by the nano-vesicles formed by PMM (Fig. 3(a)
and (b)). Moreover, the entrapped drug can be released easily
by simple addition of a biocompatible metal salt, such as KCl,
into the drug-loaded vesicles, which was confirmed by fluores-
cence microscopic images (Fig. 3(c) and (d)). This encapsulation–
Notes and references
1 W. Zhang and R. A. Laursen, FEBS Lett., 1999, 455, 372–376.
2 Z. Shen, H. Yan, Y. Zhang, R. L. Mernaugh and X. Zeng, Anal. Chem.,
2008, 80, 1910–1917.
3 F. Baneyx and D. T. Schwartz, Curr. Opin. Biotechnol., 2007, 18,
312–317.
4 S. Santoso, W. Hwang, H. Hartman and S. Zhang, Nano Lett., 2002, 2,
687–691.
5 T. H. Han, J. S. Park, J. K. Oh and S. O. Kim, J. Nanosci. Nanotechnol.,
2008, 8, 5547–5550.
6 G. Demirel, N. Malvadkar and M. C. Demirel, Langmuir, 2010, 26,
1460–1463.
7 M. Reches and E. Gazit, Isr. J. Chem., 2005, 45, 363–371.
8 X. Yan, Q. He, K. Wang, L. Duan, Y. Cui and J. Li, Angew. Chem.,
2007, 119, 2483–2486.
9 X. Yan, P. Zhu and J. Li, Chem. Soc. Rev., 2010, 39, 1877–1890.
release process was further confirmed by fluorescence emission 10 J. K. Lee and B. R. Lentz, Biochemistry, 1997, 36, 6251–6259.
11 R. de la Rica and H. Matsui, Chem. Soc. Rev., 2010, 39, 3499–3509.
12 M. P. Del Borgo, A. I. Mechler, D. Traore, C. Forsyth, J. A. Wilce,
study (Fig. 3(e)). The fluorescence of the MTX drug is found to
drop enormously after encapsulation of it by the peptide nano-
M. C. J. Wilce, M.-I. Aguilar and P. Perlmutter, Angew. Chem., Int. Ed.,
vesicles. After incubation of the drug-encapsulated peptide
2013, 52, 8266–8270.
2640 | Chem. Commun., 2014, 50, 2638--2641
This journal is ©The Royal Society of Chemistry 2014